Medicenna Advances MDNA11 and Bizaxofusp Clinical Programs
TORONTO and HOUSTON, August 14, 2026 Medicenna Therapeutics Corp. reported its first-quarter fiscal 2027 financial results and provided a...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
TORONTO and HOUSTON, August 14, 2026 Medicenna Therapeutics Corp. reported its first-quarter fiscal 2027 financial results and provided a...
BETHESDA, Md., August 6, 2026 Northwest Biotherapeutics announced that it has entered into a non-binding Memorandum of Understanding (MOU)...
MALLORCA, Spain, July 23, 2026 Laminar Pharmaceuticals S.A. has announced the successful completion of patient recruitment for the CLINGLIO...
LONDON, United Kingdom, July 20, 2026 GSK plc has announced that the European Medicines Agency (EMA) has accepted its...
TEL AVIV, Israel & OSLO, Norway, July 20, 2026 BioLineRx Ltd. and Hemispherian AS have announced that new preclinical...
NEW YORK, July 9, 2026 IN8bio announced the publication of peer-reviewed Phase 1 clinical trial results for its investigational...
BETHESDA, Md., July 2, 2026 Northwest Biotherapeutics announced that its Chief Technical Officer, Dr. Marnix Bosch, will deliver a...
BALTIMORE, June 29, 2026 CraniUS Therapeutics has received an initial $1.1 million award through the National Institutes of Health...
SAN FRANCISCO, Calif., June 26, 2026 Siren Biotechnology has been awarded an $8 million non-dilutive CLIN2 grant from the...
STAMFORD, Conn., June 24, 2026 Knoa Pharma LLC and the Global Coalition for Adaptive Research (GCAR) announced a significant...
